Cuba’s citizens are well known for free medical care, and the medical institutions in this Caribbean island country have also developed some new special medicine treatments, which have enabled many patients to find here from Wan Li, not far from all over the world. Treating intractable diseases has become another feature of Cuban medical care.

　　[Special medicine for auxiliary treatment of lung cancer]

　　CIMAvax-EGF, an adjuvant drug for lung cancer, is a unique drug developed by Cuban Center for Molecular Immunology and registered in 2008. It can strengthen the human immune system and give chemotherapy time to respond, thus improving the treatment effect of lung cancer.

　　Eduardo Osito, deputy director of the Cuban Center for Molecular Immunology, said that the research and development of CIMAvax-EGF exhausted the efforts of the first generation of scientists in the center. It is mainly composed of epidermal growth factor (EGF) and another protein P64K. Cuban medical personnel realize that EGF molecules play a very important role in the process of tumor evolution. "CIMAvax-EGF does not directly kill cells, but it can make them hungry by preventing EGF from attaching to the cell’s self-sensor," Osito said. "This correlation is the key to prevent cell growth and proliferation."

　　Unlike many other cancer therapies that have serious side effects, patients who use CIMAvax-EGF have a good tolerance to drugs. According to Osito, 30% of patients treated with this drug have significantly improved their quality of life.

　　In view of the current treatment situation of the drug, scientists believe that it is likely to have potential curative effect on cancer cells such as head and neck cancer and colon cancer that depend on EGF growth.

　　Cuba’s national medical system used this special medicine for the first time in 2012, and thousands of patients have benefited so far. At present, four countries use this medicine.

　　In January this year, Roseveare Park Cancer Institute cooperated with Cuba, and the drug began clinical trials in the United States, and it is planned to be approved by the US Food and Drug Administration (FDA) for use in the American market.

　　[Gold Award-winning Diabetes Drugs]

　　Heberprot-P is a new special medicine introduced by Cuba in 2006 for treating diabetic foot ulcers. Its appearance has saved a large number of patients from amputation.

　　The medicine is a unique product developed by Jorge Bellanga, a Cuban scientist, and the team of the Center for Genetic Engineering and Biotechnology. It contains the active pharmaceutical ingredient of epidermal growth factor (EGF) and works by direct infiltration or injection into the injured area.

　　Dr. Manuel Raisez, a member of the research team of the Center, said: "With each injection, amino acids and protein compounds can differentiate cells, and healthy and energetic tissues begin to be injected into the ulcer site. After an average of about three months, the wound is completely healed."

　　In 2007, Cuba built a clinic specializing in treating diabetic foot ulcers, but the demand far exceeded expectations. The Cuban Ministry of Health decided to start a national treatment project, and there are 458 specialized clinics at present.

　　Laissez said: "This makes our current diabetes amputation rate in the world the lowest, only 3.8%." He said that there are nearly 1 million diabetic patients in Cuba, and there are about 35,000 cases of diabetic foot ulcers every year. In 2016, only 480 cases were actually amputated.

　　Laissez and scientists from the Center have given lectures on the drug and its use in more than 20 countries, including Russia, Kuwait, Algeria, Argentina, Ecuador and Venezuela. At present, Heberprot-P has been registered in 23 countries and has been effectively used in 10 countries.

　　The implementation of this project in Cuba has been internationally recognized. It was launched to the international market 10 years ago and won the gold medal of intellectual property rights awarded by the World Health Organization.

　　[biopharmaceuticals become Cuban characteristics]

　　The research and development of new special drugs reflects the achievements of Cuba in developing medical biotechnology industry for many years. Dengue fever in the early 1980s prompted Cuba to develop Interferon；, which can stop potential viruses. In 1990, the hepatitis B recombination vaccines was developed, which almost eliminated hepatitis B in Cuba. A single dose vaccine called Heberpenta can protect against diphtheria, tetanus, whooping cough, hepatitis B and influenza B.

　　Other famous drugs developed in Cuba include Pentavalente for treating virus infection, Estreptokinasa for treating heart disease, PPG for treating cholesterol disease, Nimotuzumab for treating head and neck cancer, Eritropoyetina Human Recombinants for chronic anemia and granulocyte colony stimulating factor (g-csf) in leukemia patients.

　　Cuba has also developed many botanical drugs. The Natural Medicine Center under the National Scientific Research Center of Cuba uses palm tree fruit extract to make drugs for treating benign prostatic hypertrophy; Extracted from local wild plants in Cuba and made into drugs for autoimmune diseases; Abexol；, an antioxidant drug with anti-aging effect made from purified beeswax extract; Calcium supplement Suplecal；; Prevenox； for treating osteoporosis; PPG for controlling cholesterol level made from sugarcane extract, etc.

　　[Special medicine breeds medical tourism]

　　In the 1990s, in order to reverse the huge impact on Cuba’s economy after the disintegration of the Soviet Union, the Cuban government made great efforts to develop the tourism industry in order to obtain the foreign exchange badly needed by the country. With Cuba’s opening up to foreign tourists, tourists found that Cuba had a high success rate in treating many diseases, some of which were even better than their own countries, and medical tourism came into being.

　　Established in 1987, Cuban Medical Service Agency (SMC) mainly provides medical services for foreigners. Dr. Ianna Alvarez, director of the agency’s sales department, told reporters that SMC has signed agreements or established strategic partnerships with about 41 countries, that is to say, SMC has cooperative relations with some institutions, medical insurance companies, service export units or clinics that transport patients to Cuba for treatment.

　　Patients who come to Cuba for treatment through SMC come from all over the world, including Canada, Europe, the United States, Central America and South America. The needs of patients in Cuba are different. Many Canadian patients come to Cuba for cosmetic or plastic surgery, such as lumbar replacement, hip replacement, knee prosthesis and other treatments. Such operations need to wait for a long time in many countries; Central and South American patients come to receive nervous system treatment; Europeans mainly come to perform various eye operations and treat psoriasis, lung cancer or foot ulcers with drugs developed by Cuba …

　　Because patients come to Cuba for treatment through different channels, SMC does not have complete data, but one thing is certain, that is, the demand of international patients is increasing every year, so Cuban health authorities begin to open new foreign-related institutions and facilities in large hospitals.

　　According to Alvarez, China and Cuba have established cooperation in medical services. She said: "Because China and Cuba are far apart, it is difficult to launch a comprehensive plan for Chinese to be treated in Cuba. However, once patients have accurate information about treatment, I believe they will have high satisfaction. "

　　Alvarez said that Cuban medical services will send professionals to China to promote health care projects in the future, so that more Chinese can understand and benefit from Cuban medical services. (Ma Guihua) (special feature of Xinhua News Agency)

　　After the Hong Kong stock market closed at 16: 30 on February 19, Meituan announced that it would pay social security for full-time and stable part-time riders nationwide, which is expected to be implemented in the second quarter of 2025.

　　Following the launch of the anti-fatigue mechanism and the cancellation of overtime deduction, this is another measure taken by Meituan to improve the social security of new employment groups in recent years. According to public information, since July 2022, Meituan has taken the lead in paying new occupational injury insurance premiums for new employment groups. At present, it has invested 1.4 billion yuan to pay occupational injury insurance premiums for riders in seven pilot provinces and cities, and will further cover all riders in all provinces and cities in the future.

　　If this round of social security payment is gradually implemented, it may eventually benefit more than one million riders. According to public reports, in 2023, there were about 820,000 "stable riders who received orders for more than 260 days in a year", which should include the "full-time and stable part-time riders" described in the announcement of the US Mission. Considering that the scale of the take-away market and employment groups is still expanding, it is estimated that it may eventually cover more than one million riders.

　　According to industry insiders, with the steady development of take-away and other industries, at present, a relatively clear division of "professional" and "part-time" groups has been formed among new employees such as take-away riders. Many riders have become stable practitioners after accumulating relevant experience and skills. Providing all kinds of security for stable employment is not only in line with the actual interests of workers, but also conducive to the long-term development of the industry and the formation of a relatively stable and professional distribution group.

　　It is worth noting that since the beginning of the year, Meituan has continuously introduced heavy measures to strengthen the protection of new employment groups, including canceling overtime deductions and online anti-fatigue mechanisms, and has built 16,000 rider communities in conjunction with all sectors of society to help riders smooth the distribution path.

　　At the end of the announcement, the US Mission stated that "it will continue to increase resources and capital investment, continuously improve the rider welfare treatment system, and strive to contribute more positive forces to building harmonious labor relations."

Fuzhou Strait International Convention and Exhibition Center, the main venue of the 2nd Digital China Construction Summit.

　　Cctv news(Reporter Zhang Xiaolin, Wang Xiaoying and Li Wenliang) From May 6 to 8, the second Digital China Construction Summit will be held in Fuzhou, Fujian Province.

　　Digital China Construction Summit is a platform for publishing China’s informatization development policies, displaying the achievements of e-government and digital economy development, exchanging theoretical experience and practice of digital China construction, and gathering global forces to promote the construction of digital China. The theme of this summit is "Cultivating new kinetic energy with informatization, promoting new development with new kinetic energy, and creating new glory with new development".

　　Compared with the first summit in 2018, the new positioning has injected international elements into this summit and added a lot of highlights to this summit.

　　Aspect 1: Big coffee drives insight into the new trend of industry development

　　This summit will hold the opening ceremony, main forum, sub-forum, achievement exhibition, report release, innovation competition and closing ceremony.

　　At present, this summit has collected and sorted out a total of 498 digital economy docking projects with a total investment of 407.5 billion yuan. Ma Huateng, Chairman of Tencent’s Board of Directors, and Li Yanhong, Chairman of Baidu, have confirmed their attendance at the summit. At the same time, more than 40 academicians of the two academies, as well as guests from leading enterprises of digital economy such as Huawei, Baidu, Ali, Tencent, Inspur and Iflytek, will attend the conference, and will give wonderful speeches in the main forum and related sub-forums. The number of guests attending the conference is expected to increase by 50% compared with the first summit.

　　Aspect 2: The collision of views in 16 sub-forums is more exciting

　　Compared with the first session, not only the number of guests has increased, but also the number of sub-forums this year has doubled from 8 to 16.

　　In addition to e-government, big data, smart society, digital economy, digital Fujian, digital Haisi, Internet of Things, the sub-forum has also added digital ecology, satellite applications, industrial Internet, network technology, digital health and other contents, with more detailed themes, greatly increased focus and more intense point of view collision.

　　It is noteworthy that the organizing committee of this summit will invite some international organizations, multinational companies, foreign-funded enterprises in China and think tank representatives to participate, and will also invite government officials from countries along the Belt and Road to participate in the summit activities, share their views and exchange mutual learning.

　　Aspect 3: Pay attention to the policy release and grab the "red envelope" of the ministries.

　　Policy release will continue during this year’s summit. The Central Network Information Office, the Ministry of Agriculture and Rural Affairs, the National Health Commission, the National Space Administration and other ministries and commissions will focus on releasing policies on industry informatization and digital economy development in their respective fields, and launch a number of policy "red envelopes".

　　In the main forum, the responsible comrades of the National Internet Information Office will release the Report on the Construction and Development of Digital China (2018). At the closing ceremony, relevant national ministries and commissions will also release relevant policies and reports.

　　Aspect 4: See the exhibition and experience the new technology.

　　As a platform for releasing China’s information development policies and displaying the achievements of e-government and digital economy, what new technologies will be exhibited at the Digital China Construction Achievements Exhibition? Everyone is curious.

　　It is reported that this summit has added a sub-forum on industrial applications, and the exhibition area has increased from 40,000 square meters to about 60,000 square meters. The exhibitors basically cover all provinces, municipalities and relevant state ministries and commissions, as well as many top 100 Internet companies and top 100 electronic information companies. The development achievements of digital China and digital economy in recent years will be fully displayed, and the first exhibition rate of new technologies and new products will exceed half.

　　There are five major venues in this exhibition, and the themes are comprehensive+digital Fujian, guest province+digital government, digital economy (digital industrialization), digital economy (digital industry)+achievement release and smart society+digital life+achievement release.

　　The organizer will also launch a number of smart application scenarios in the venue, such as full-scene face payment, smart restaurants, credit blocks, driverless cars, and unmanned vehicles, and realize the full coverage of the 5G signal main venue, bringing a batch of 5G and intelligent new experiences to the guests. In addition, an "online summit" was launched to create a "year-round exhibition and never ending" summit.

　　Aspect 5: Take the entrepreneurial platform to see who is competing with the front.

　　The finals of the Digital China Innovation Competition will be held during the summit.

　　According to the organizer, the 2019 Digital China Innovation Competition aims at outstanding data scientists at home and abroad, and sets three kinds of algorithm problems: big data, artificial intelligence and industrial internet, so as to explore innovative technology applications and business models, stimulate the innovation vitality of professionals, and build a new platform for Industry-University-Research cooperation in high-tech industries.　

　　The 2019 Digital China Innovation Competition Finals will publicly defend and review the outstanding works of 18 teams that have advanced in the regional finals, and select excellent teams of data scientists and solutions to promote the in-depth integration of the new generation of information technology and traditional industries, help solve the pain points and difficulties in the development of digital economy, and help the construction of digital China.

Spring Festival in 2025: Wu Ershan and Jia Ling are competing for each other, and Stephen Chow will become a dark horse?

The film market in 2024 has been settled after several important schedules.

Looking back on this year, except for YOLO and Pegasus 2, which performed brilliantly in the Spring Festival, almost all the films in the other schedules were unsatisfactory, especially in the summer and National Day, which made the audience feel disappointed.

However, with the approach of the Spring Festival in 2025, it seems that the film market will usher in a new "fairy fight".

It is reported that there will be at least seven blockbuster films competing for release in the Spring Festival next year, which not only makes people start to guess which film can dominate the box office, but also makes movie fans eager to try.

So, among these seven films, who is most likely to be the ultimate winner?

The first appearance was "Nobody 2" directed by Rao Xiaozhi.

As a sequel to Nobody, this film is highly anticipated.

The previous work has an excellent reputation, with Douban scoring as high as 8 points, which has accumulated a large number of loyal audiences.

This time, the story of "Nobody 2" is completely independent and revolves around the old story of the small factory owner played by Chen Jianbin.

A mysterious order involved Lao Wen in a storm halfway around the world, full of suspense and drama.

Judging from the plot, "Nobody 2" still continues Rao Xiaozhi’s style, wrapping profound social problems with a comedy shell.

Coupled with the joining of powerful actors such as Andy Lau and Chen Minghao, this film is expected to become a dark horse for the Spring Festival.

Ne Zha once swept the box office in 2019 and became the pinnacle of domestic animation.

Now, the long-awaited sequel "Nezha’s Magic Children Making a Sea" is finally coming to the fore.

This film has a very wide audience, and both children and adults can find pleasure in it.

Judging from the box office potential, "Nezha’s Magic Children Making a Sea" is likely to continue the glory of its previous work.

It not only has exquisite visual effects, but also combines traditional myths with modern values, which is enough to attract a large number of audiences into the cinema.

As a rare animated film in the Spring Festival, it may become one of the dark horses at the box office.

Chen Sicheng’s detective chinatown 1900, as another heavyweight film in the Spring Festival, naturally attracted much attention.

The film is a prequel to the Tang Detective series, which tells the adventures of the characters played by Wang Baoqiang and Haoran Liu around 1900.

With the familiar characters, tense plot and Chen Sicheng’s comedy suspense style, it is obvious that this film has a good chance to continue the box office legend of Tang Tan series.

However, it is still a challenge for Chen Sicheng to get rid of the shadow of the rollover of Decryption.

If the storyline and logic line are properly designed, the box office breakthrough should be reasonable.

The success of "Feng Shen I" has undoubtedly won a lot of praise for Wu Ershan, and "Feng Shen II" will also appear in the Spring Festival next year.

As a domestic top special effects blockbuster, the film is undoubtedly a strong competitor in the Spring Festival file visually.

Although the negative news of young actors may have a certain impact on word-of-mouth, the performances of ChristianRandPhillips, Li Xuejian and Bo Huang are still the highlights that the audience most expect.

The plot of the film is based on the classic myth of China. Although the story has long been known, the audience still has high expectations for this epic visual presentation.

As long as the film is well-made, it is still possible for Wu Ershan to create a box office miracle in the Spring Festival.

When it comes to martial arts movies, you have to mention Tsui Hark.

This time, he brought The Legend of the Condor Heroes: The Great Man, starring Sean Xiao.

Guo Jing, played by Sean Xiao, aroused extensive discussion among the audience as soon as he appeared. Some people called him "the most handsome Guo Jing in history".

As a veteran of martial arts movies, Tsui Hark undoubtedly has a top control over the visual effect and action design of the film.

Although the casting of Huang Rong, the heroine of the film, is controversial, Tsui Hark has always had the ability to create classic female characters.

Therefore, the overall quality of this film is worth looking forward to, and it is also expected to achieve good results at the box office with Sean Xiao’s super popularity.

After Hi, Mom, Jia Ling’s Turn to Flowers once again attracted great attention from the audience.

This time, Jia Ling gave up the pure comedy route and chose the anti-pyramid scheme theme with criminal elements.

The film, starring Jia Ling, Zhang Xiaofei and Andy, revolves around an anti-MLM story.

Jia Ling once proved that she is good at grasping the emotional pain points of the audience, and this crime theme may open a new chapter for her directing career.

If the plot is compact and profound, the film is likely to gain both word-of-mouth and box office.

Stephen Chow’s Mermaid 2 is highly anticipated.

Although Master Xing has not directed new films in recent years, he frequently appeared in the public eye in 2024, participated in talk shows, replayed classic films and other actions, which seemed to pave the way for Mermaid 2.

Although this movie has been skipped for many years, the appeal of Master Xing cannot be underestimated.

If this work can be released as scheduled in the Spring Festival in 2025, it may become the biggest dark horse and rekindle the popularity of Xingye movies.

tag

The 2025 Spring Festival file can be called the "fairy fight" in the film market.

No matter from the director’s lineup or the cast, it can be said that there are many stars.

Wu Ershan, Jia Ling, Chen Sicheng, Stephen Chow and other big names in the film industry have gone into battle one after another. The film types cover comedy, animation, crime, suspense, martial arts and other topics, which almost meet the needs of different audiences.

Nowadays, the audience is also facing "phobia of choice". Which movie can stand out depends on whether the story itself touches people’s hearts.

Whether it’s the social depth of Nobody 2, the animation charm of Nezha’s Devil’s Child Naughting the Sea, or the emotional touch of Flowers Turning, each film has its own unique competitiveness.

Which one are you looking forward to most?

　　"Daming Fenghua", as the only outstanding costume drama "Blowout" at the end of the year, has lived up to expectations and caused a wide discussion. Around the "Daming’s First Family", many figures appeared in turn. Unexpectedly, the most striking thing was not Tang Wei, who premiered the TV series, but the role played by Wang Xueyin — — Ming Chengzu Zhu Di.

　　Due to the unavoidable complex historical evaluation of usurping the throne and seizing power, the battle of Jing Nan, Zhu Di was rarely shown positively in film and television dramas in the past, and Daming Fenghua pushed it to the foreground for the first time. Wang Xueyin’s interpretation shows the lonely king’s iron and blood thunder in front of people, his regret and helplessness behind people, his high degree of self-discipline and self-examination and his deep hatred for his loved ones. His eyebrows, figure and body are full of drama. It is hard to believe that he is a 73-year-old man, regardless of his artistic expression or the mental state of the whole person.

　　Recently, Wang Xueyin was interviewed by Beijing Youth Daily, revealing how Zhu Di, the first successful "out of the circle" in historical dramas, was born.

　　Atypical emperors and princes

　　The special feature of Daming Fenghua is that it focuses on describing the family interaction of Zhu family for generations and the complex emotional entanglements between characters, and shows the traditional royal family culture. No wonder some people say, "I can watch 100 more episodes of Lao Zhu family’s daily life." In particular, Wang Xueyin and Guanhua Liang, two old opera bones, played an atypical pair of emperors and princes: father Zhu Di was overbearing and powerful, and used means to punish his heart; Zhu Gaochi, the son, is loyal and generous in nature. He has worked hard but has no credit. He is passive to Nuo Nuo in front of his father, and when he returns to the Prince’s Mansion, he will suffer greatly … … Their opposite plays are very beautiful.

　　In Wang Xueyin’s eyes, this version of Zhu Di’s "addiction" is because the screenwriter endowed the character with unprecedented richness with precise lines, rather than the "cage-raising birds and harem things all day" in traditional imperial dramas. Wang Xueyin said that Zhu Di in "Ming Fenghua" is good-looking and good-looking, and there is no disguise in his merits and demerits. "He knows that he has made a big mistake and laments that it is ‘ A thief who has never been easy ’ However, the history books are required to be written realistically, and sinners are sinners; At the same time, he is also strict with himself, and he is brilliant. He is more confident than ever. "

　　Simple life likes complex performances.

　　The only thing that is more dramatic is that when Zhu Di was majestic, Wang Xueyin suppressed Guanhua Liang by thunder, and when he was short in his parents’ family, his appearance and manner were closer to his brothers. When I check my resume, Wang Xueyin is 73 years old and Guanhua Liang is 55 years old — — From the actual age, there is no problem for them to play father and son.

　　In terms of age, Wang Xueyin really doesn’t look like he’s over seventy. Asked how to maintain such a good physical condition, Wang Xueyin summed it up in two words — — Simple. "I’m a soldier, used to obey orders, let the left to the left, let the right to the right, never ask why. I never think about wearing clothes. I don’t have complicated interpersonal relationships, no one else thinks so much, and there is not so much distress. " Wang Xueyin said.

　　It’s so simple that I just like to perform it all my life, and the "complex" energy after meeting my beloved role is also admirable. Wang Xueyin revealed that he was not enthusiastic about costume drama. "Wearing that dress is fake, it is too far away from us, and the feelings are not touching.". At first, I agreed to look at the script of Daming Fenghua simply because I appreciated the talent of director and screenwriter Zhang Ting. "The first time I cooperated with Zhang Ting was" Entrepreneurial Times ".He was a screenwriter and his lines were particularly good. In one scene, the director said the words were too long, so delete them. I said that I can’t delete it. There are too few opportunities to meet such a good line. Please wait for me for 20 minutes. " The whole group stopped to cooperate, and finally Wang Xueyin made several lines in one go.

　　Details show the king’s difficulties

　　Seeing the script of "Daming Fenghua", Wang Xueyin’s prejudice against costume drama disappeared, and he did not hesitate to take on Zhu Di. "I have played all my life and know that it is too difficult to meet a good drama. I am glad that I met Yellow Land in my first play. At that time, I was young and didn’t understand it. I didn’t think it was a good script. I didn’t promise to shoot it and acted in a drama. Only later did I know its value. "

　　In Daming Fenghua, there are scenes such as Zhu Di’s fight against an iron fist, hesitation, reluctance, tears, and gathering his children and grandchildren to swear together that they can no longer be stained with their own blood, which is considered to be "whitewashed". In this regard, Wang Xueyin denied that these details did not whitewash Zhu Di, but moved the audience because they showed subtle and true feelings between men. "Zhu Di brought up his three sons alone and didn’t marry again. Put a lot of energy into them. As an emperor, there are inevitably many contradictions with children. How to discipline children and how to choose successors all require means and wisdom. This play does not blindly say that he is good, but shows the difficulties of a generation of kings from all aspects. " (Text/Reporter Yang Wenjie)

　　CCTV News:The data shows that the proportion of users who use mobile phones to watch videos exceeds 70%, and watching videos and live broadcasts on the move has become the urgent need of the majority of users. In order to meet the audience’s strong demand for watching live broadcasts on mobile phones, Glory has joined hands with China Telecom and CCTV Easy Orange to give away 90GB of telecom traffic free of charge to users who buy Glory’s 5C full netcom version since August.

　　Traffic is free to send live broadcasts.

　　According to the statistics released by CNNIC, 71.9% of users use mobile phones to watch videos, and the current hot live broadcast has intensified this trend. However, in most cases, WiFi signals are only available indoors. Although the speed of 4G network is fast, the huge traffic consumption has become the most troublesome problem for users.

　　In order to enable users to watch mobile video and live broadcast anytime and anywhere, Glory teamed up with China Telecom and CCTV Easy Orange to launch a special event: giving away 90GB of free traffic from China Telecom (*90GB of telecom traffic, which is directed traffic for CCTV Integrated application, only applicable to Glory Play 5C Full Netcom Edition). Users of China Telecom who purchase Glory 5C full netcom version can upgrade their mobile phone system to the latest version (B121 version or above), and open the built-in "CCTV Comprehensive" APP in their mobile phones to receive the traffic for free. The traffic will take effect on the same day, and they will be given for 6 months in a row, and 15G of local directional traffic will be given every month (subject to the operator’s notice).

　　In the "CCTV Comprehensive" APP built in Glory Play 5C Netcom Edition, the traffic consumed by users to watch programs will be deducted from the 90GB free traffic.

　　Glory and play 5C, enjoy it for a long time.

　　Glory Play 5C Full Netcom Edition is equipped with Kirin 650 chip with 16 nm 8-core, which is the first time to introduce the 16 nm process technology of the same generation as flagship models such as iPhone6s and Huawei Mate8 into the thousand yuan machine market. Compared with the 28 nm chip mobile phone on the market, Glory Play 5C performance is improved by 65%, and the power consumption of the whole machine is reduced by 40%. At the same time, it supports 4G+ technologies such as carrier aggregation and Cat.6, and the downlink speed can reach up to 300Mbps.

　　In this way, under the extremely fast 4G network, using the Glory 5C equipped with 16 nm 8-core to watch live video, the buffer is fast, the load is fast, the video is more refreshing, the heat is less, the power consumption is less, and the video can be played for a longer time, thus getting rid of the double pain that the progress bar can’t be dragged and the traffic can’t be hurt.

　　Watch the wonderful things anytime, anywhere.

　　CCTV mobile TV service was officially launched in December, 2006. It is committed to building the first cross-media interactive mobile TV station in China and providing the most authoritative, convenient and beautiful mobile video viewing service for mobile phone users in China. Information broadcast at home and abroad, the first time to take you to the news site; The hot events in the European Cup and the Olympic Games continue; CCTV famous columns, Spring Festival Gala, two sessions, military parade and other exclusive hot columns, witness the passionate moment of major events! Now all you need is a glory to play 5C full netcom version, which is exciting anytime and anywhere, and 90GB free traffic is waiting for you!

　　Beijing Yi Orange Tianxia Technology Co., Ltd. is a wholly-owned subsidiary of CCTV, and the only authorized operator of CCTV’s mobile TV integrated broadcast control license and content service license; It is the only channel for CCTV’s massive and high-quality copyright content to be exported to mobile terminals. Approved by the State Administration of Radio, Film and Television, the call sign of CCTV mobile TV content service license is "CCTV mobile TV" and the call sign of integrated broadcast control license is "China mobile video".

　　Purchase link:

　　vmall

　　http://www.vmall.com/product/3451.html#67053624

　　Tian Mao Rong Yao Guan Fang flagship store

　　https://detail.tmall.com/item.htm? spm=a1z10.1-b.w11380389-14230140659.12.oa7llY&id=533764239378

　　Suning.cn Rong Yao Guan Fang flagship shop

　　http://product.suning.com/0070086258/159010969.html

　　JD.COM Rong Yao Guan Fang flagship shop

　　http://item.jd.com/3141994.html

On December 25th, the staff inspected the product packaging quality in the Covid-19 inactivated vaccine sub-packaging workshop of China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, the staff inspected the product packaging quality in the Covid-19 inactivated vaccine sub-packaging workshop of China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, the staff worked in the Covid-19 Inactivated Vaccine Sub-packaging Workshop of China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, I photographed the products being packaged in the Covid-19 Inactivated Vaccine Sub-packaging Workshop of China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, the staff worked in the Covid-19 Inactivated Vaccine Sub-packaging Workshop of China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, the staff checked the information before shipment from the vaccine cold storage of China Biological Beijing Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, the staff opened the delivery port from the vaccine cold storage of China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, a cold-chain truck loaded with inactivated Covid-19 vaccine departed from China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On December 25th, the staff conducted an artificial light inspection in the sub-packaging workshop of Covid-19 inactivated vaccine in China Institute of Biological Products of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On April 11th, the staff tested the samples of novel coronavirus inactivated vaccine in the quality inspection department of China Bio-COVID-19 Vaccine Production Base of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On April 10th, the staff cleaned the equipment in the inactivated vaccine production workshop in novel coronavirus, which has not been put into production in China Bio-COVID-19 Vaccine Production Base of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On April 10th, the staff took a group photo outside the delivery window of novel coronavirus inactivated vaccine production workshop in China Bio-COVID-19 vaccine production base of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

On April 12th, the first volunteer was inoculated with novel coronavirus inactivated vaccine developed by China Institute of Biological Products of Sinopharm Group in Wuzhi County Center for Disease Control and Prevention, Jiaozuo City, Henan Province.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua news agency

On June 23rd, the launching ceremony of the International Clinical Phase III of COVID-19 Inactivated Vaccine developed by Sinopharm Group China Biotech was held in the United Arab Emirates.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua news agency

On April 11th, the staff tested the samples of novel coronavirus inactivated vaccine in the quality inspection department of China Bio-COVID-19 Vaccine Production Base of Sinopharm Group.

China has taken a crucial step in fighting the COVID-19 epidemic! The joint prevention and control mechanism of the State Council was released on December 31st. The Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing in National Medical Products Administration, and its protection effect meets the requirements of relevant standards of the World Health Organization and National Medical Products Administration, and will be provided free of charge for the whole people in the future.

The listing of Covid-19 vaccine in China injected confidence into the global victory over the epidemic and provided strong support for the vaccine to become a global public product.

Xinhua News Agency reporter Zhang Yuwei photo

　　In 1995, China put forward the idea of "going out" in agriculture, and in 2007, the No.1 document of the Central Committee formally put forward the idea of "going out" in agriculture as a national strategy. In the past twenty years, China’s agricultural "going out" has experienced the development process of folk initiation and national strategy implementation, and has achieved good results, but also encountered some problems. To sum up, the main achievements are as follows: (1) the accelerated growth of foreign direct investment, the increasingly extensive and diversified investment areas, methods and industries, and the rapid accumulation of investment income and experience; The main problems are manifested in three levels. First, there is a lack of self-ability at the enterprise level, such as lack of international talents and lack of overseas management experience. Second, there are obstacles to the absence of national public services at the institutional policy level, such as mismatched domestic financing policies and incomplete implementation of investment agreements among some countries; Third, there are environmental risk challenges at the host country level. In order to develop China’s agriculture globally in the future, it is necessary to assess the situation, strategize, locate accurately, ensure the overall situation and plan systematically.

　　First, size up the situation, and deeply analyze the strategic situation of China’s agricultural development going global.

　　(A) The present stage is a period of great strategic opportunities for China’s agricultural development to go global.

　　Judging that the present stage is a period of great strategic opportunities for China’s agricultural development to go global, it is based on the following three facts: First, China’s national strength has been rapidly improved, and it already has the national strength to plan agricultural development on a global scale. Second, the world’s undeveloped agricultural resources are still abundant, and there is still huge room for China’s agricultural development to go global. It is timely for China’s agricultural development to go global by making use of the world’s agricultural development potential, filling the regional gaps and bridging the gap in the industrial chain. Third, the rapid growth of agricultural enterprises in China and the mature development of agricultural technology have created the profound internal strength for China’s agriculture to go global. It is timely for China’s agricultural development to go global, with export-oriented leading agricultural industrialization enterprises as the master and advanced and applicable agricultural technologies as the sharp weapon.

　　(B) The current world development trend is generally beneficial to the global development of China’s agriculture.

　　Judging the world development trend is generally beneficial for China’s agricultural development to go global, based on the comprehensive evaluation of the following challenges and opportunities: First, although there are still downside risks in world development and the prices of bulk agricultural products are in a depression, the global economy is in a post-crisis recovery period, the global monetary policy is generally loose, developing countries such as China and India strengthen economic reforms, and Asian, European and African countries actively respond to the "One Belt, One Road" initiative advocated by China. The recovery of the world economy is expected, the demand for agricultural products will be further expanded, and China’s agricultural development will move towards a global economic environment. Second, China’s agricultural "going out" has increasingly highlighted the concepts of "pro-,sincerity, benefit, tolerance" and "harmony", emphasized common development and mutual benefit, helped the agricultural development of the host country, won the hearts of the people and gained friendship, and the international environment for China’s agricultural development to go global has become more and more favorable. Third, although the risks of overseas agricultural operations are prominent, the overseas investment of Chinese agricultural enterprises to the world is growing steadily, with an average annual growth rate of more than 20%. The strategic tools to deal with various risks are gradually enriched, and the ability to identify, deal with and control risks is also significantly enhanced.

　　Second, strategize and reposition the strategic goal of China’s agricultural development going global.

　　At present, the global economic development is getting better for a long time, the international pattern is profoundly adjusted, the risks are identifiable, avoidable, preventable and controllable, and the international environment is generally favorable. Going global is a major choice for China’s agricultural development in the new period. We should strategize, accurately position, clearly define the goals and develop with the trend.

　　First of all, we should establish the concept of "harmonious development", adhere to the motto of "pro-,sincerity, benefit and tolerance", and realize the win-win cooperation between China’s agriculture and the agricultural development of the host country. Secondly, we should clearly set the following goals: expand the development space of China’s agriculture, and enhance the global competitiveness, resource allocation, market control and international influence of China’s agriculture. Third, it is necessary to make clear the main body of China’s agricultural development going global, with large multinational agricultural enterprises dominated by China capital as the core body, small and medium-sized overseas investment agricultural enterprises actively participating in the global agricultural market as beneficial participants, relevant financial institutions, intermediaries and think tanks as the providers of core services, and government departments as the providers of key policies and public services. Finally, we should carry out the following ideas: consider and comprehensively apply the two international and domestic markets, two resources and two types of rules, actively implement the deployment of the "Belt and Road Initiative", accelerate the implementation of agricultural "going out", lay out the global agricultural industrial chain, build a number of key multinational agricultural enterprises, deeply integrate and control the key links and major value-added nodes of the global agricultural industrial chain, and build an efficient and sustainable global agricultural product supply and demand coordination network and a global allocation network of agricultural science and technology and resources.

　　Third, make sure of the overall situation and systematically plan the strategic countermeasures for China’s agricultural development to go global

　　(1) Strengthen strategic planning and support at the national level.

　　It is a strategic choice at the national level for agricultural development to go global. It is necessary to make strategic planning, strengthen state support, carry out long-term strategic planning and implementation, and continuously strengthen macro guidance and service capabilities for agriculture to go global. The strategic deployment of China’s agricultural development going global should obey and serve the overall situation of the country’s development, coordinate and promote each other with the country’s diplomatic strategy, foreign investment strategy and foreign aid strategy, and realize the national interests to the greatest extent. Strategic planning should pay attention to gradual progress and divide strategic development stages. At the present stage, we should focus on developing stable agricultural products trade and providing agricultural assistance to developing countries. In the medium term, we should focus on overseas agricultural investment and international agricultural cooperation. In the long term, we should aim at building large-scale multinational agricultural enterprises, building a global agricultural product supply and demand adjustment network and an agricultural science and technology and resource allocation network.

　　(B) to strengthen the cultivation of large multinational agricultural enterprises

　　Multinational agricultural enterprises are the key subjects to enhance the global competitiveness, resource allocation, market control and international influence of China’s agriculture. Encourage all kinds of enterprises to increase overseas agricultural investment; As soon as possible, select a group of multinational agricultural enterprises with a certain scale, good development foundation, experience and foundation in foreign agricultural investment and development, strong economic strength and sufficient reserves of talents, especially international management talents, to give key support; We will build a group of powerful international agricultural enterprises that can operate flexibly and develop for a long time in the international agricultural industrial chain and international agricultural products market, compete with the four international agricultural enterprises of ABCD on the same stage, and have the status of China.

　　(3) Deepening and expanding international cooperation in agriculture.

　　Actively implement the "Belt and Road Initiative" and strengthen agricultural trade and agricultural economic and trade cooperation between China and countries along the "Belt and Road"; Implement the development concept of "harmony", focus on strengthening agricultural assistance and cooperative development of agricultural resources in developing countries or regions, and strive to improve the self-sufficiency and export supply capacity of agricultural products in developing countries; Strengthen close trade and investment cooperation with developed countries with rich agricultural resources, actively participate in their comprehensive agricultural development and global supply chain construction, and increase the effective supply of global agricultural products through multiple channels.

　　(D) Layout of the global agricultural industrial chain

　　From the perspective of the layout of the whole industrial chain, we should make reasonable arrangements in agricultural scientific research, agricultural research and development, production, processing, logistics, warehousing and sales, and make long-term plans to form the control ability of the whole industrial chain. Can be distributed to agricultural production related fields, provide technical training and services for local producers, and exchange technology and services for products and markets; Extend to the field of agricultural products processing to realize the value-added of agricultural products; Extend to infrastructure construction and lay out the logistics system of agricultural products transportation. The government should actively support Chinese agricultural enterprises to lay out key nodes in the global agricultural industrial chain, and form a diversified win-win situation with resource development and cooperation in the whole agricultural industrial chain as the core. Guide and support agricultural enterprises to tilt towards capital and technology-intensive industries such as processing, logistics, warehousing and docks, as well as key areas with high technology content such as research and development, improve the level of agricultural foreign investment, and continuously optimize the investment structure.

　　(Author: Institute of Agricultural Economics and Development, Chinese Academy of Agricultural Sciences)

Unconsciously, the Spring Festival holiday has ended, and many people have returned or are on their way back. Are you ready to start the work mode? What should I pay attention to before and after returning? What adjustments are needed to start work, diet, work and rest after the holiday?

After the Spring Festival holiday, many people set foot on the return journey. What should they pay attention to before, during and after the trip? After the long vacation, some people may have symptoms such as sleep disorder, anxiety and depression. How to alleviate and deal with "holiday syndrome"? A picture to understand.

Is it difficult for you to eat on time? Rushing to work and class in the morning, giving up breakfast after breakfast; Working overtime until late at night, you can only fill your stomach with snacks and supper. Even in order to lose weight, eating one less meal every day is designated as a personalized "rule" for eating.

Original Tencent medical code　

Never think that "vaccination is a child’s business". Even if you are an adult, it is very important to vaccinate in time & it is very important to replenish the vaccine that was missed before.

According to the report of the Centers for Disease Control and Prevention (CDC), 50,000 to 90,000 American adults die of vaccine-preventable diseases every year, such as pneumococcal diseases, influenza and hepatitis [1], and this statistic does not count cervical cancer caused by HPV (more than 5,000 people died of cervical cancer in the United States in 2018 [2]).

In this article, we have summarized 9 vaccines that adults need to consider:

Influenza vaccine: suitable for children and adults over 6 months old.

Herpes zoster vaccine: suitable for people over 50 years old.

23-valent pneumococcal polysaccharide vaccine: recommended for people with special health conditions over 2 years old and the elderly.

HPV (human papillomavirus) vaccine: suitable for all women aged 9-45.

Hepatitis A vaccine, hepatitis B vaccine and hepatitis E vaccine: Adults should also be vaccinated in time.

Chickenpox vaccine, measles, rubella and mumps vaccine: special circumstances, protecting adults.

If you don’t want to read the text, you can directly drop it down to the end of the article. We have sorted out the suitable vaccination population and vaccination methods of these nine vaccines in detail, and summarized them into a table for you to save to your mobile phone for comparison.

Many people misunderstand the lethality of the flu and think that the flu is just like a cold.

In fact, influenza is a very dangerous respiratory infectious disease.

Influenza can cause 290,000 ~ 650,000 respiratory disease-related deaths worldwide every year [3].

Maybe you will think, "I’m an adult and I’m in good health, so I don’t have to fight."

But unfortunately, the flu is a disease that the whole population is susceptible to. Even if they are not sick, adults are running around every day, and it is easy to bring the flu virus back to the elderly or children at home.

Therefore, people of all ages over 6 months old are advised to complete influenza vaccination in autumn and winter every year, preferably before the end of October [3].

(Long press the picture to save it to the phone)

The pathogen of herpes zoster is called varicella-zoster virus (VZV), which is a neurovirus.

People who have experienced the onset of herpes zoster, the biggest feeling is "pain"-pain like knife cutting, fire and electric shock.

Many people even say that it is comparable to childbirth pain and cancer pain. In fact, the pain of herpes zoster can also lead to suicide [4].

As long as you have been infected before (such as chicken pox when you were a child), the virus may lurk in the body for a long time. Once your immunity drops, it will come out and "mess up", leading to herpes zoster.

There is no specific treatment for this disease at present, and vaccination is the most effective way to prevent it [5].

Therefore, it is recommended that people aged 50 and above should be vaccinated against herpes zoster as much as possible.

(Long press the picture to save it to the phone)

Don’t think that "pneumonia is nothing to be afraid of". In fact, in addition to "pneumonia", Streptococcus pneumoniae is an important pathogen causing meningitis, otitis media, bacteremia and other infections, and it is also the main cause of community-acquired pneumonia.

About 1 million people worldwide die of pneumococcal pneumonia every year, and the mortality rate among the elderly and high-risk groups is as high as 30%~40%[6].

Vaccination with 23-valent pneumococcal polysaccharide vaccine can effectively prevent 23 common Streptococcus pneumoniae infections that lead to invasive diseases.

The elderly aged 60 and over, as well as the special population over 2 years old, are recommended to be vaccinated with 23 valent pneumococcal polysaccharide vaccine.

(Long press the picture to save it to the phone)

Studies have shown that 99.7% of cervical cancer is related to HPV infection [7].

At present, there are three kinds of HPV vaccines on the market, 2-valent, 4-valent and 9-valent. Many people subconsciously think that the 9-valent vaccine is the best. In fact, within the allowable age, the sooner you get HPV vaccine, the better. It is best to get it before you have sexual experience.

If there is a shortage of 9-valent vaccine in your area and it is difficult to make an appointment, you don’t have to force it to be 9-valent.

(Long press the picture to save it to the phone)

It has been more than 40 years since the immunization program in China, during which it has undergone several changes: the immunization program vaccine has expanded from 4 to 14, and the preventable infectious diseases have expanded from 6 to 15.

This means that from the current standards, some adults born earlier may miss some vaccines.

You can look for your own vaccination registration book to check the relevant information, or ask your parents about their own vaccination. If you can’t remember whether you have been vaccinated, you can treat it as "not vaccinated".

If you have not been vaccinated with the following vaccines, you need to consider replanting.

Hepatitis A, B and E vaccine

China is a big country with hepatitis. Viral hepatitis with great harm mainly includes:

Hepatitis A and hepatitis E transmitted through digestive tract, and hepatitis B and hepatitis C transmitted through blood, mother and child [8].

1. Hepatitis A

Hepatitis A vaccine was only included in the immunization program in 2008, so many adults have not been vaccinated.

Although hepatitis A has been considered to be well controlled, in recent years, the incidence group of hepatitis A in China is mainly adults. Take Liaoning as an example, the local incidence is mainly adults. The vaccination target of adult hepatitis A vaccine is ≥16 years old, and children are vaccinated at the age of 12 months to 15 months.

2. Hepatitis B

Hepatitis B, which makes many people turn pale, has been effectively controlled in recent years, but it is estimated that the number of patients still exceeds 84 million, and in 2018, more than 90% of hepatitis B virus infected people are adults over 20 years old [9].

What needs to be vigilant is that hepatitis B may also transmit the virus to children through mother-to-child transmission.

3. Hepatitis E

Hepatitis E may be very strange to many people, but in fact, there are more than 28,000 cases in China, even more than hepatitis A [10].

Moreover, few people know that hepatitis E, like hepatitis A, is transmitted through the digestive tract, and even less people know that hepatitis E can be prevented by vaccines.

Therefore, if you have never been vaccinated with these three vaccines, you should complete the vaccination as soon as possible according to your own situation.

(Long press the picture to save it to the phone)

Varicella vaccine

Many people think that chickenpox is a disease that only children get. In fact, adults occasionally get sick, and the risk of complications and death of adults with chickenpox is higher than that of children [12].

Chickenpox virus is very easy to spread in a confined space, so it is recommended to vaccinate teachers, white-collar workers, pregnant women and people who may have close contact with chickenpox patients.

Anyone who has never had chickenpox, or who has only had one shot in the past, can be vaccinated or replanted.

(Long press the picture to save it to the phone)

MMR vaccine

The full name of this vaccine is "live attenuated measles, mumps and rubella vaccine", which can be abbreviated as "MMR vaccine".

The measles-mumps vaccine can stimulate the body to produce immunity to measles virus, mumps virus and rubella virus at the same time, thus preventing measles, mumps and rubella.

All three viruses can spread through droplets and are highly contagious.

Moreover, if a woman is infected with rubella during pregnancy, it may lead to congenital rubella syndrome in the fetus, resulting in irreversible consequences such as abortion and congenital malformation of the fetus [13].

In China, measles vaccine was mainly covered in the early years, and it was not until 2007 that measles vaccine was fully covered.

Therefore, most people born before 2007 suggest re-vaccination.

(Long press the picture to save it to the phone)

Finally, we have summarized the nine vaccination methods mentioned in this article for you in the following table.

(Long press the picture to save it to the phone)

references

[1]Reid KC, Grizzard TA, Poland GA. Adult immunizations: recommendations for practice. Mayo Clin Proc. 1999 Apr; 74(4):377-84. doi: 10.4065/74.4.377. PMID: 10221468.

[2]HPV Information Centre. United States of America Human Papillomavirus and Related Cancers, Fact Sheet 2018.

[3] China Center for Disease Control and Prevention, Influenza Vaccine Working Group of National Immunization Planning Technology Working Group. Technical Guide for Influenza Vaccination in China (2020-2021).

[4]Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, Hasnaoui A El, de Labareyre C. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001; 33:62–69.

[5] Herpes Zoster Expert Consensus Working Group of Dermatologists Branch of Chinese Medical Association. Herpes Zoster Expert Consensus in China. Chinese Journal of Dermatology 2018; 51(6): 403-8.

Chinese Preventive Medicine Association and Vaccine and Immunity Branch of Chinese Preventive Medicine Association. Expert Consensus on Immunoprophylaxis of Pneumococcal Diseases (2017 Edition) [J]. Chinese Journal of Preventive Medicine .2018,19 (3): 161-191.

[7]Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8(2):e191––e203.

[8] National Health and Family Planning Commission of the People’s Republic of China. China Viral Hepatitis Prevention and Control Plan (2017-2020) [J]. China Journal of Viral Diseases, 2018.

[9]Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19(1):811. Published 2019 Sep 18.

[10] Brief introduction of epidemic situation of Class A, B and C infectious diseases in China in December 2020 [J]. Disease Surveillance, 2021,36(01):1.

[11]Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, Koneru A, Haber P, Hagan L, Romero JR, Schillie S, Harris AM. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3; 69(5):1-38.

[12]Meyer, Pamela, A, et al. Varicella Mortality: Trends before Vaccine Licensure in the United States, 1970-1994.[J]. Journal of Infectious Diseases, 2000.

[13]Gary s. Marshall. Translated by Zhou Zumu. Vaccine Manual: A Practical Guide for Clinicians [M]. 4th Edition. Beijing: Peking University Medical Press, 2014.

Read the original text